Therapeutic and vaccine strategies against SARS-CoV-2: past, present and future

Mubasher Rehman¹, Isfahan Tauseef¹, Bibi Aalia², Sajid Hussain Shah¹, Muhammad Junaid¹ & Kashif Syed Haleem*,¹

¹Department of Microbiology, Hazara University, Mansehra 21300, Pakistan
²Pediatric Department, KMU Institute of Medical Science, Kohat, Pakistan
³Pediatric Department, Ayub Teaching Hospital, Abbottabad, Pakistan
*Author for correspondence: kashifhaleem@hu.edu.pk

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease 2019. It was first reported in Wuhan, China and has since become a global health concern. Keeping in view, the magnitude of the problem, scientists around the globe are working to develop effective therapeutic strategies. This review focuses on previous findings regarding SARS-CoV, which may prove helpful in future research on SARS-CoV-2. In addition, it also highlights recent developments in medicine and biotechnology toward developing effective drugs and vaccines against SARS-CoV-2. This review will analyze available data on this topic and will help researchers develop new thoughts using information already available as a step toward developing novel therapeutic strategies against SARS-CoV-2.

Global prevalence

According to latest reports by the WHO, as of 1 May 2020, total cases of COVID-19 worldwide were 3,175,207 accounting for 224,172 deaths. In Africa, 26,663 confirmed cases and 973 deaths were reported, while in America, 1,291,917 confirmed cases and 69,087 deaths have been reported. In Eastern Mediterranean, 188,585 confirmed cases and 7598 deaths were confirmed. In Europe, 1,461,404 confirmed cases were reported among which 138,200 died because of COVID-19. In South East Asia, 57,088 cases have been confirmed among which 2174 died, while in the Western Pacific, 148,838 confirmed cases have been reported with 6127 deaths (Table 1) [3].
Table 1. Total number of cases worldwide as reported by WHO on 1 May 2020.

| Continent            | Reported cases | Death toll | Case fatality rate (%) |
|----------------------|----------------|------------|------------------------|
| Globally             | 3,175,207      | 224,172    | 7.06%                  |
| Europe               | 1,461,404      | 138,200    | 9.45%                  |
| Americas             | 1,291,917      | 69,087     | 5.34%                  |
| Eastern Mediterranean| 188,585        | 7598       | 4.02%                  |
| Western Pacific      | 148,838        | 6127       | 4.11%                  |
| South East Asia      | 57,088         | 2174       | 3.80%                  |
| Africa               | 26,663         | 973        | 3.64%                  |

Table 2. Therapeutic strategies against SARS-CoV-2.

| Strategy                        | Methods                      | Mode of action                                                                 | Examples/under trial drugs                                                                                                                                                                                                 | Ref.          |
|---------------------------------|------------------------------|--------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------|
| Receptor inhibition             | a. ACE2 receptor inhibition  | Inhibition of viral receptors on host cell by different compounds interfere with Spike or part of Spike refolding | Baricitinib, ruxolitinib, natural hesperidin, nafamostat mesylate, camostat mesylate and other antiviral drugs                                                                                                          | [9,12–15]    |
|                                 | b. TMPRSS2 inhibition        |                                                                                  |                                                                                                                                                                                                                             |               |
| Antiviral drugs                 | a. Antiviral drugs specifically designed for SARS-CoV-2 | To identify the viral proteins and stop the replication of virus | Lopinavir/ritonavir, IFN-α, arbidol, favipiravir and darunavir etc., (all these drugs are already approved for other viral infections but now are under clinical trial against SARS-CoV-2). remdesivir, chloroquine and ivermectin are recently US FDA approved drugs for SARS-CoV-2 infection. | [16–18]      |
|                                 | b. Antiviral drugs already used for other viral infections (such as HIV, hepatitis, influenza etc.) |                                                                                  |                                                                                                                                                                                                                             |               |
| Immunotherapy                   | a. Complement system         | Suppressing/inhibiting or enhancing the body immune response/s | C3a, C5a inhibitors, CYNK-001, tocolizumab, rapamycin                                                                                                                                                                      | [19–24]      |
|                                 | b. NK cell therapy           |                                                                                  |                                                                                                                                                                                                                             |               |
|                                 | c. IL-6 inhibitors           |                                                                                  |                                                                                                                                                                                                                             |               |
|                                 | d. mTOR inhibitors           |                                                                                  |                                                                                                                                                                                                                             |               |
| Vaccination                     | a. RNA vaccines              | Helps the immune system of the body to identify and to fight against infectious pathogens by providing acquired immunity (In all these vaccines target is S protein except live attenuated and killed vaccine for which the whole virion is the target) | Currently, more than 115 vaccines are developing for example: mRNA-1273 (RNA vaccine by Moderna Inc.), INO-4800 (DNA vaccine by Inovio Pharmaceuticals Inc.), ChAdOx1nCov-19 (killed/inactivated vaccine by Oxford University, AstraZeneca Plc.), Ad5-nCov (live attenuated vaccine by CanSino Biologics Inc.) and NVX-CoV2373 (recombinant protein vaccine by Novavax Inc and by Clover Biopharmaceuticals). | [25–27]      |
|                                 | b. DNA vaccines              |                                                                                  |                                                                                                                                                                                                                             |               |
|                                 | c. Recombinant protein vaccines |                                                                                  |                                                                                                                                                                                                                             |               |
|                                 | d. Live attenuated vaccines  |                                                                                  |                                                                                                                                                                                                                             |               |
|                                 | e. Killed/inactivated vaccines |                                                                                  |                                                                                                                                                                                                                             |               |
|                                 | f. Viral vector-based vaccines |                                                                                  |                                                                                                                                                                                                                             |               |
| Other therapeutic options       | a. Plasma therapy            | Inhibit viral replication or to boost body immune response | Artemisia annua (medicinal plant), plasma from patient recovered from nCoV infection is used in plasma therapy. Protease inhibitors such as lopinavir, atazanavir and indinavir | [28–31]      |
|                                 | b. Medicinal plants          |                                                                                  |                                                                                                                                                                                                                             |               |
|                                 | c. Protease inhibitors       |                                                                                  |                                                                                                                                                                                                                             |               |
|                                 | d. Monoclonal antibody       |                                                                                  |                                                                                                                                                                                                                             |               |

NK: Natural killer; SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2.

Treatment strategies for COVID-19

Currently, no specific antiviral agent is available against SARS-CoV-2 infection, with clinically proven efficacy as in case of MERS-CoV and SARS-CoV [6,7]. To understand SARS-CoV replication, different animal models have been used and they showed severe infection symptoms. On the other hand, no pathogenesis was detected in case of MERS-CoV because of DDP4 receptor noncompatibility in mice [8]. For studying SARS-CoV-2 pathogenicity, SARS-CoV animal models can be used because SARS-CoV-2 is 80% similar to SARS-CoV. SARS-CoV-2 entry into host cells is thought to be similar to SARS-CoV, possibly through ACE2 cell receptor [9]. As per various genomic organization studies [10] and molecular mechanisms of SARS-CoV-2 pathogenesis [11], there are numerous targets, which can be used in different ways as therapeutic agents to inhibit the virus replication or to develop an intervention which may be effective against SARS-CoV-2. Various therapeutic (drugs), immunotherapeutic and Vaccination strategies against SARS-CoV-2 are summarized in Table 2 and subsequently discussed below.

Therapeutic strategies (drugs)

ACE2/TMPRSS2 receptor inhibition

Virus initially binds to a host cell through targeted receptors. Previous studies on SARS-CoV revealed that the primary targets of this virus are epithelial cells, macrophages and other cells in the lungs. All these cells have ACE2
which is used by SARS-CoV for attachment and entry [32–34]. Another study on immune response kinetics documented that cell spike (S) and hemagglutinin (H) are the anchoring proteins of SARS-CoV-2 with the help of which virus binds with host cells. S and H proteins are present on the surface of the virus and help in attachment with host cell receptor ACE2 and with sialic acid receptors respectively [33]. It was observed that increased infectivity of SARS-CoV-2 as compared with SARS-CoV is because of a furin-like cleavage site present on its S protein [35]. Along with furin pre-cleavage, TMPRSS2 also aids in the host cell entry and SARS-CoV-2 spike protein processing [36].

It was hypothesized that one way to stop SARS-CoV-2 infection is to saturate or block the ACE2 receptors or TMPRSS2 by using different molecules and antibiotic, which resultantly restrict virus from binding to the host cell and ultimately control the replication cycle [12]. Different drugs already approved for treatment of other conditions can be used to inhibit endocytosis mediated by ACE2. One such example is baricitinib used in treating rheumatoid arthritis. Similarly, Janus kinase could possibly be used for ACE2 inhibition [37]. Later this year, ruxolitinib, another Janus kinase inhibitor will be tested for COVID-19 treatment [38]. Another study reported that natural hesperidin can also be used to inhibit the ACE2 receptor [12]. Addition of a high concentration of ACE2 in a soluble form may reduce the entry of the virus into targeted host cells. Using different small molecules, which interfere with spike or part of spike refolding can possibly control the infection of virus [12,39]. Another study docked antiviral drugs with 21 possible targets based on their docking result. Findings revealed that among all possible dock targets, three of these namely Nsp3b, Nsp3c and E-channel are the suitable antiviral drugs. The effects of antiviral drugs on these targets need more research focus [12].

For TMPRSS2 inhibition, no clinical drug has yet been specifically tested in case of COVID-19 except for the camostat mesylate which stopped virus entry into the lung cells [36,37]. On the other hand, in case of other infections, clinical trials of nafamostat mesylate [40,41] and Camostat mesylate [36] have already been approved for TMPRSS2 inhibition. Anti-corona virus activity of imatinib has previously been reported as it inhibits the endosomal membrane and viral fusions [42]. Involvement of ACE2 receptors in facilitating viral entry into the cells makes them potential antiviral drug targets to control the entry of virus into the host cell.

Antiviral drugs

Antiviral drugs are designed in such a way that they identify the viral proteins and stop the replication of virus instead of killing them as antimicrobials do. By stopping the replication cycle, they tend to reduce the number of pathogens to a certain level where they are unable to induce pathogenesis and allow the body’s own immune response to neutralize the virus [43].

WHO, US FDA, European Medicines Agency (EMA) and the Chinese government and drug manufacturers have coordinated with different institutes and industrial scientists to develop antiviral drugs. The International Clinical Trials Registry Platform of the WHO approved hundreds of the clinical studies to carry out and test postinfection therapies for COVID-19 infections [16,44] with many antiviral drugs already used for treatments of other infections [17,18,45]. These drugs have previously been tested and used against HIV, malarial parasites, influenza viruses, hepatitis C virus etc. Some of the antiviral drugs, which have been tested in vitro as inhibitors of SARS-CoV-2 infection are: IFN-α, previously used to treat hepatitis infection and has shown to inhibit the replication of SARS-CoV [46]. Hence, this drug may possibly inhibit the replication of SARS-CoV2. In vitro as well as clinical studies have documented that Lopinavir/ritonavir, an HIV drug has anti coronavirus activity [47,48]. Antiviral drug arbidol which is used against influenza virus has also proven to be effective in inhibiting infection caused by SARS-CoV-2 [49]. Favipiravir and darunavir drugs which are used against novel influenza and HIV also showed anti-SARS-CoV activity [49,50].

According to one study, it was suggested that remdesivir and chloroquine can be used to treat COVID-19 infected patients because they showed promising effects in vitro [40,51]. Based on these findings, FDA approved the antiviral drug remdesivir for the treatment of laboratory-confirmed COVID-19 adults and children; however, no evidence exists about the safety and effectiveness of remdesivir [52]. Prevention is the utmost way to control infection.

Ivermectin, an antiparasitic drug has also been approved recently by the FDA against COVID-19 after successful inhibition of replication of SARS-CoV-2 in vitro [53].

All these drugs can be good choices to treat COVID-19 infections. No specific antivirals have yet been reported which may be fully effective against COVID-19. Scientists are working hard to find out the potential drugs but there is a need to do more clinical and preclinical trials of these drugs to test the efficacy and safety in COVID-19 treatment. Different drugs targeting viral replication at different steps have been shown in Figure 1.
**Immunotherapeutic strategies**

*Immunotherapeutic use of the complement system*

The complement system is one of the vital components of the innate defence system of the human body which acts as a bridge between innate and adaptive immunity. It consists of more than 35 proteins and regulators. The research on the complement system is progressing rapidly after the establishment of its role in inflammation and a potential therapeutic effect against certain diseases. There are two main types of complement immunotherapy: one in which immune response is enhanced (by using a recombinant form of complement proteins, etc.) while in other type, body’s immune responses are suppressed to control the disease by different inhibitors and biomolecules [54,55]. In case of SARS-CoV-mediated acute respiratory distress syndrome, it was observed that the C3 component of complement activation further worsens the disease. As SARS-CoV is closely related to SARS-CoV-2, it can be speculated that the same mechanism could possibly occur in case of COVID-19. Animal models of SARS-CoV also revealed that mice deficient in C3 showed limited respiratory dysfunction [56].

This clearly indicates that inhibition of C3 can be utilized as an effective treatment in case of SARS-CoV-2. In *in vivo* infection model studies of AMY-101 (C3 inhibitor) showed that it interferes with IL-6 release [57]. Data on acute respiratory distress syndrome and SARS-CoV-2 is very limited; however, according to a recent report, it was observed that COVID-19 patients displayed a widespread activation of complement proteins, C3a and C5a [58]. All these findings clearly indicate that C3a and C5a inhibitors, as well as other known biomarkers of inflammations...
can be used to treat COVID-19 patients. More studies need to be conducted to investigate the potential use of the complement system as a therapeutic strategy against SARS-CoV-2.

**Natural killer cell therapy**

Besides boosting antibody responses, enhancing cell mediated immunity is also under consideration. Natural killer cells, also known as K or killer cells, are components of the innate immune system, which play a major role in controlling tumours and rejection of virus-hijacked cells, hence restricting the pace of replication and subsequent tissue damage. Recently, the FDA approved investigational new drug CYNK-001 for Phase I/II clinical studies in COVID-19 patients. Initially, CYNK-001 was developed from placental hematopoietic stem cells and was suggested for the treatment of various haemolytic cancers and solid tumours such as multiple myeloma, myeloid leukaemia and glioblastoma multiforme. Different studies revealed that during viral infection, there is vigorous activation of natural killer cells and CYNK-001 has the potential to express natural cytotoxic receptors as well as activating receptors which bind with viral antigen on infected cells. Due to these functions, it was suggested that CYNK-001 may be used in inhibiting the replication of SARS-CoV-2 and progression of COVID-19 by eradicating the infected cells [19].

**IL-6 Inhibitors**

A couple of recent studies have suggested the effectiveness of tocilizumab in critical patients infected with corona virus. A significant improvement in these patients was observed after its use which ultimately reduced the dependence of patients on artificial oxygen support [20,21]. A likely explanation to this phenomenon is that being IL-6-receptor inhibitor antibody, it breaks the chain of interaction between components of inflammatory cascade, ultimately reducing the effects of cytokine storm. More detailed studies are underway to further elaborate its pros and cons. Several IL-6 inhibitor monoclonal antibodies are under clinical trials (ClinicalTrials.gov identifier NCT04315298 and NCT04331808). Few other anti-inflammatory therapeutic agents, for example, Janus kinase inhibitors, glucocorticoids and chloroquine/hydroxychloroquine have also been suggested for comparatively early recovery of SARS-CoV-2 infected patients [59].

**mTOR pathway inhibition**

In SARS-CoV-2 infection, several altered pathways, for example, ‘IL-17 signalling pathway’, ‘cytokine-mediated signalling pathway’ and ‘defense response to other individuals’ were identified using gene term enrichment analysis [60]. A cytokine storm was also evident, clearly indicating the irregularities and dysfunctionalities in host defense system. These exaggerated innate inflammatory responses and associated dysfunctions in adaptative immune responses are the root cause of tissue damage in COVID-19 infection [61].

Scientists are seeking the novel therapeutic strategies to combat COVID-19 infection. One such novel strategy is to exploit the mTOR for controlling infection. mTOR1, mTOR2 and AMPK are the associated pathways of mTOR [22,62]. The main function of mTOR pathway is to regulate the survival, growth, proliferation and metabolism of the cell. It is also involved in controlling the lipids metabolism, synthesis of proteins, transcription and autophagy as it senses the extracellular as well as intracellular signals [63].

A recent study has speculated that at an early stage of COVID-19, cross-reactive antibodies production against SARS-CoV-2 can be reduced if memory B cells are inhibited selectively, which ultimately reduce the antibody dependent enhancement process, which may contribute toward initiating cytokine storm and make the symptoms worse. mTOR pathway inhibitors, such as rapamycin, have the potential to selectively inhibit the memory B cells leading to a reduction in early-stage crossreactive antibodies against SARS-CoV-2 and resultanty less antibody dependent enhancement [64]. Another study also suggested that sirolimus, an mTOR inhibitor, can be a perfect drug of choice in SARS-CoV-2 infected patients [60]. In addition, the inhibitor also helps in the suppression of potent CD4+ effector T cell and promotion of Treg [65,66]. Rapamycin has already been shown to exert antiviral activities against HIV and other viruses like vaccinia and influenza [67–71].

**Vaccination strategies**

One of the most effective ways to prevent a disease is vaccination. Vaccine helps the immune system of the body to identify and fight infectious pathogens by inducing acquired immunity. The vaccine contains an inactive or attenuated pathogen, or one of its surface proteins or its toxins, which activate the immune system of the body and
keeps us protected from the disease they cause [72]. To control the outbreaks of coronavirus, it is necessary to make a vaccine which helps in reducing the severity, shedding and transmission of the virus.

There are numerous strategies of vaccinations for SARS-CoV-2 such as RNA vaccines, DNA vaccines, Recombinant protein vaccines, live attenuated vaccines, killed/inactivated vaccines and viral vector-based vaccines. In all these vaccines, target is S protein except the live-attenuated and killed vaccine for which the whole virion is the target. Along with many advantages, they have several disadvantages. Against MERS-CoV and SARS-CoV, these strategies have already been tested using animal models [73,74] and many of them are in first clinical-stage trials. Developing a final vaccine after these trials may take several months to many years. S protein has been considered as an ideal target for SARS-CoV and MERS-CoV vaccine. Since it is established that SARS-CoV2 has almost 80% structural similarity with SARS-CoV, S protein is a promising target which can act against both types of viruses [25].

During initial studies of the SARS-CoV vaccine, it was observed that live virus results in lung damage by inducing immunopathological reactions like inflammation and infiltration of eosinophils along with other complications hence worsening the outcome of disease [75,76]. Along with these complications, it is also necessary to examine the effect of the virus during recurrent infection as it is common in SARS-CoV infection. Hence, during vaccine trials for SARS-CoV-2, it is necessary to address these complications and effects to ensure efficacy and safety.

Currently, more than 115 vaccines are under investigation against SARS-CoV-2 in different universities, research institutes, drug companies, biotechnology firms, health organizations and several research groups [26]. Even if the research is progressed at a fast pace, it may take several months to develop the first vaccine in the record time by using one of the vaccine strategies discussed above. Currently, it is impossible to guess which strategy will be faster and more effective. mRNA based vaccines are under clinical trials by Moderna Inc, Curevac is also trying to develop a similar vaccine using this approach. Recombinant protein-based vaccines are also being investigated by Expression, iBio, Novavax, Baylor College of Medicine, University of Queensland and Sichuan Clover Biopharmaceuticals (focusing on S protein). Vaxart, Geovax, University of Oxford and Cansino Biologics are creating a viral vector-based vaccine (focusing on S protein). Codagenix with the Serum Institute of India, etc. are focusing to develop live attenuated vaccines while DNA vaccines are under trail by Inovio and Applied DNA Sciences with focus on S protein [73]. For COVID-9, Johnson & Johnson and Sanofi also joined hands to create a vaccine by using adenovirus vector platform and Flublok recombinant influenza virus vaccine respectively [27,77,78]. However, these efforts may take at least several months to develop a vaccine which is readily available for human.

Bacille Calmette-Guérin (BCG) vaccine is also thought to reduce the COVID-19 impact, thus could play an important role against SARS-CoV-2 (Curtis et al.). It has a beneficial off-target/nonspecific positive effect on the immune system which may help in an early recovery of COVID-19 patients, as found previously against several respiratory infections [79,80]. In controlled trials, the BCG vaccine reduced the infection severity caused by certain viruses having structural similarities with SARS-CoV-2 [81,82]. Different clinical trials are underway in Australia and Netherland to investigate the effectiveness of BCG vaccine in COVID-19 susceptible individuals especially health workers (ClinicalTrials.gov identifier NCT04327206, NCT04328441, NCT04384549, NCT04348370 and NCT04414267) [83,84]. If successful, use of the BCG vaccine would be a crucial tool against COVID-19 infection and other future pandemics. However, for the time being, there is a need to stick to the recommendations of WHO [85].

Other therapeutic options

Plasma therapy is another therapeutic strategy used against COVID-19 patients just like SARS-CoV [86] and MERS-CoV [87] in which plasma from recovered patients was injected to infected individuals. Initially, it showed promising results in COVID-19 patients, still further extensive studies are required to investigate if this therapy is worth application keeping in mind complications associated with other plasma proteins. Contini [28] in his research suggested two protease inhibitors for COVID-19 treatment, which have previously been used against HIV infection [28]. The recombinant human monoclonal antibody is one of the other promising therapeutic candidates for infections caused by COVID-19 [29]. For the treatment for SARS-CoV-2, other monoclonal antibodies, already used against SARS-CoV, can be used as an alternative strategy to treat infection [30].

Plants have been used for centuries as therapeutic agents against several diseases, including viral infections. Several medicinal plants have been studied in past against different viral diseases due to the presence of a repository of antiviral metabolites like alkaloids, flavonoids, terpenoids and phenols [88]. Many Chinese scientists have screened several natural products and medicinal plants among which they suggested nine plants and recommended that they might have a role in inhibition of viral replication [12,31].
Conclusion

This review has presented various strategies which can be used to control COVID-19 infection. COVID-19 pandemic has infected millions of people worldwide and claimed several thousand deaths. Scientists and researches around the globe are working to explore potential therapies against this deadly virus. Different strategies like controlling of replication of the virus, inhibiting the binding of the virus to host cells, use of molecules and compounds to boost innate as well as passive immunity or to screen drugs effective against other viruses can be effective and quick ways to treat COVID-19. Until now there is no approved drug available against SARS-CoV-2 and hundreds of the vaccines and antiviral drugs are under clinical trials which will take several months to be made available in the market. Some antiviral drugs and strategies have shown significant effects in vitro, yet there is a need to confirm their efficacy and safety in preclinical and clinical trials. It is hoped that by using these strategies, scientists will develop new, fast, accurate, effective, cheap and safe therapeutic compound against SARS-CoV-2.

Current scenario & future perspective

COVID-19 emerged at the global scene very recently and rapidly spread across the globe in a couple of months giving scientists very limited time to respond. New drugs and vaccines development usually take years if not decades. The sudden outbreak of COVID-19 caused by a virus, new to the human race, created panic in the scientific community. It was impossible to develop a new drug or vaccine within months or year. Short term approach suggested by scientists for the treatment of COVID-19 patients was to investigate drugs already in practice against other diseases and check their efficacy against SARS-CoV-2. For vaccine development, scientists throughout the world responded rapidly with the help of funding from Govts and industrial sectors and conducting research at a very fast pace. Hence a large number of vaccines are under investigation with some showing promising results.

Luckily SARS-CoV-2 is the sister strain of previously reported SARS-CoV and MERS viruses. Past studies performed against these two strains of coronaviruses are providing a strong baseline for drugs and vaccine development against SARS-CoV-2. Some of the strategies have proven very effective in vitro and in animal models. Many have been approved for clinical trials. Hence it is hoped that the human race will be successful in discovering effective drugs for the treatment of severe COVID-19 patients. Besides, some positive news in vaccine development suggest that very soon new vaccines will be available in the market and it will become possible to create a herd immunity against this virus, limiting the spread of this deadly virus and eradicating it from the face of the earth as in case of so many viruses in past.

Author contributions

M Rehman wrote and compiled the manuscript. I Tauseef contributed writing specific section. B Aalia contributed and reviewed clinical aspect. SH Shah contributed and reviewed drug section. M Junaid reviewed and revised the paper. KS Haleem conceived and designed the theme of manuscript and reviewed.

Funding & competing interests disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.
Executive summary

Background
- COVID-19 is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) also known as 2019 novel coronavirus.
- For SARS-CoV-2 infection, currently, no specific vaccine or antiviral agent is available with clinically proven efficacy. Scientists across the globe are working to develop a vaccine, drug and exploring possible ways to treat this infection.

Drugs
- ACE2 receptors inhibitors naturally came across as the major targets of interest for scientific community because of established knowledge that the virus initially binds to a host cell through these receptors. Drugs like baricitinib, ruxolitinib, natural hesperidin and nafamostat mesylate are being investigated to inhibit ACE2 receptors.
- Type II transmembrane serine protease inhibition is also being considered by scientists. Nafamostat mesylate and camostat mesylate have already been approved for type II transmembrane serine protease inhibition.
- Antiviral drugs are usually aimed to stop the replication of virus instead of killing, allowing the body's own immune response to neutralize the virus.
- The International Clinical Trials Registry Platform of the WHO-approved hundreds of clinical studies to investigate different antiviral drugs already used for treatments of other infections.
- Some of the examples are IFN-α, previously used to treat hepatitis infection. Lopinavir/ritonavir, HIV drugs have displayed some anti coronavirus activity. Similarly, antiviral drug arbidol, favipiravir and darunavir drugs used against HIV and influenza have exhibited some anti-SARS-CoV activity.
- USA FDA approved the antiviral drug remdesivir and ivermectin (an antiparasitic drug) against COVID-19.

Immunotherapy
- Although the major focus of therapeutic strategies is on vaccination by using the adaptive immune system, some scientists are suggesting to boost the innate immune system against SARS-CoV-2.
- One of these strategies is to suppress inflammation by blocking the activity of complement protein C3. Complement plays an important role in enhancing inflammation that complicates the disease at later stages leading to severe pneumonia.
- The second strategy is enhancing the function of natural killer cells. A drug like CYNK-001 has the potential to express natural cytotoxic receptors as well as activating receptors which bind with viral antigen on infected cells, creating more sites on virus hijacked cells to be identified by natural killer cells.
- Other Immunotherapeutic approaches like IL-6 and nTOR inhibitors are also under consideration.

Vaccination
- Vaccination is the best strategy to prevent a disease by facilitating indigenous immune system of the body to identify and fight against infectious pathogens.
- Various strategies of vaccinations for SARS-CoV-2 such as RNA vaccines, DNA vaccines, recombinant protein vaccines, live attenuated vaccines, killed/inactivated vaccines and viral vector-based vaccines are under investigation.
- Currently, more than 115 vaccines are under investigation. Majority of vaccine strategies are targeting S protein except the live-attenuated and killed vaccine for which the whole virion is the target.

Other therapeutic options
- Other therapeutic strategies like plasma therapy, protease inhibitors for COVID-19 treatment, the recombinant human monoclonal antibody and medicinal plants are being studied for their efficacy to control COVID-19 infection.

References

Papers of special note have been highlighted as: • of interest; •• of considerable interest
1. Lu H, Stratton CW, Tang YW. Outbreak of pneumonia of unknown etiology in Wuhan, China: the mystery and the miracle. J. Med. Virol. 92(4), 401–402 (2020).
•• Very first report of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
2. Chen N, Zhou M, Dong X et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 395(10223), 507–513 (2020).
3. WHO. Coronavirus disease (COVID-19) situation reports. (2020). http://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports
4. Chan JF, Yuan S, Kok KH et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet 395(10223), 514–523 (2020).
5. Huang C, Wang Y, Li X et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395(10223), 497–506 (2020).

10.2217/fvl-2020-0137 Future Virol. (Epub ahead of print) future science group
A useful report on clinical features of coronavirus disease 2019 infection.

6. de Wit E, van Doremalen N, Falzarano D et al. SARS and MERS: recent insights into emerging coronaviruses. Nat. Rev. Microbiol. 14(8), 523–534 (2016).

7. Zumla A, Chan JF, Azhar EI, Hui DS, Yuen K-Y. Coronaviruses – drug discovery and therapeutic options. Nat. Rev. Drug Discov. 15(5), 327–347 (2016).

8. Cockrell AS, Peck KM, Yount BL et al. Mouse dipeptidyl peptidase 4 is not a functional receptor for Middle East respiratory syndrome coronavirus infection. J. Virol. 88(9), 5195–5199 (2014).

9. Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus. J. Virol. 94(7), e00127–20 (2020).

10. Lu R, Zhao X, Li J et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 395(10224), 565–574 (2020).

A useful piece on genomic characterization of SARS-CoV-2.

11. Groneberg DA, Hilgenfeld R, Zabel P. Molecular mechanisms of severe acute respiratory syndrome (SARS). A detailed paper on genomic characterization of SARS-CoV-2.

12. Wu C, Liu Y, Yang Y et al. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharm. Sin. B 10(5), 766–788 (2020).

13. Glowacka I, Bertram S, Muller MA et al. Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response. J. Virol. 85(9), 4122–4134 (2011).

14. Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus. J. Virol. 94(7), e00127–20 (2020).

15. Xu X, Chen P, Wang J et al. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Sci. China Life Sci. 63(3), 457–460 (2020).

16. Maguire BJ, Guerin PJ. A living systematic review protocol for COVID-19 clinical trial registrations. Wellcome Open Res. 5(60), 2 (2020).

17. Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug. Discov. Ther. 14(1), 58–60 (2020).

18. Li G, de Clercq E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat. Rev. Drug Discov. 19(3), 149–150 (2020).

19. Warren NJ. Celularity announces FDA clearance of IND application for CYNK-001 in coronavirus, first in cellular therapy. (2020). http://www.prnewswire.com/news-releases/celularity-announces-fda-clearance-of-ind-application-for-cynk-001-in-c-coronavirus-first-in-cellular-therapy-301034141.html

20. Lu CC, Chen MY, Lee WS, Chang YL. Potential therapeutic agents against COVID-19: what we know so far. J. Chin. Med. Assoc. 83(6), 534–536 (2020).

21. Alattar R, Ibrahim TBH, Shaar SH et al. Tocilizumab for the treatment of severe coronavirus disease 2019. J. Med. Virol. doi: https://doi.org/10.1002/jmv.25964 (2020) (Epub ahead of print).

22. Maiese K. The mechanistic target of rapamycin (mTOR): novel considerations as an antiviral treatment. Curr. Neurovasc. Res. doi: 10.2174/1567206217666200245205122 (2020) (Epub ahead of print).

23. NIH. NK cells treatment for COVID-19. (2020). https://clinicaltrials.gov/ct2/show/NCT04280224

24. Risitano AM, Mattellos DC, Huber-Lang M et al. Complement as a target in COVID-19? J. Pharm. Anal. doi: 10.1016/j.jpha.2020.03.009 (2020) (Epub ahead of print).

25. Amanat F, Krammer F. SARS-CoV-2 vaccines: status report. A useful report on clinical features of coronavirus disease 2019 infection.

26. Thanh Le T, Andreadakis Z, Kumar A et al. The COVID-19 vaccine development landscape. Nat. Rev. Drug Discov. 19(5), 305–306 (2020).

27. Zhou Z, Post P, Chubet R et al. A recombinant baculovirus-expressed S glycoprotein vaccine elicits high titers of SARS-associated coronavirus (SARS-CoV) neutralizing antibodies in mice. Vaccine 24(17), 3624–3631 (2006).

28. Contini A. Virtual screening of an FDA approved drugs database on two COVID-19 coronavirus proteins. Chemrxiv doi: https://doi.org/10.26434/chemrxiv.11847381.v1 (2020) (Epub ahead of print).

29. Tian X, Li C, Huang A et al. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. Emerg. Microbes Infect. 9(1), 382–385 (2020).

30. Zhang L, Liu Y. Potential interventions for novel coronavirus in China: a systematic review. J. Med. Virol. 92(5), 479–490 (2020).

31. UI Qamar MT, Alqhtani SM, Alamri MA, Chen LL. Structural basis of SARS-CoV-2 3CL(pro) and anti-COVID-19 drug discovery from medicinal plants. J. Pharm. Anal. doi:10.1016/j.jpha.2020.03.009 (2020) (Epub ahead of print).

32. Hamming I, Timens W, Bulthuis ML, Lely AT, Navis G, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J. Pathol. 203(2), 631–637 (2004).

33. Jia HP, Look DC, Shi L et al. ACE2 receptor expression and severe acute respiratory syndrome coronavirus infection depend on differentiation of human airway epithelia. J. Virol. 79(23), 14614–14621 (2005).
Devaux CA, Rolain JM, Colson P, Raoult D. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? Antiviral Res. 176, 104742 (2020).

Hoffmann M, Kleine-Weber H, Schroeder S et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181(2), 271–280.e278 (2020).

One of the earliest reports on role of ACE2 and Type II transmembrane serine protease protein in SARS pathogenesis.

Richardson P, Griffin I, Tucker C et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet 395(10223), e30–e31 (2020).

Zhou J. Severe novel coronavirus pneumonia (COVID-19) patients treated with ruxolitinib in combination with mesenchymal stem cells: a prospective, single-blind, randomized controlled clinical trial. Chinese Clin. Trial Registry. (2020). http://www.chictr.org.cn/showproj.aspx?proj=49088

Martin U. APEIRON’s respiratory drug product to start pilot clinical trial to treat coronavirus disease COVID-19 in China. (2020) https://pipeline-review.com/index.php/2020022673884/Proteins-and-Peptides/APEIRONs-respiratory-drug-product-to-start-pilot-clinical-trial-to-treat-coronavirus-disease-COVID-19-in-China.html

Wang M, Cao R, Zhang L et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 30(3), 269–271 (2020).

Yamamoto M, Matsuyama S, Li X et al. Identification of nafamostat as a potent inhibitor of middle east respiratory syndrome coronavirus s protein-mediated membrane fusion using the split-protein-based cell-cell fusion assay. Antimicrob. Agents Chemother. 60(11), 6532–6539 (2016).

Coleman CM, Sisk JM, Mingo RM, Nelson EA, White JM, Frieman MB. Abelson kinase inhibitors are potent inhibitors of severe acute respiratory syndrome coronavirus and middle east respiratory syndrome coronavirus fusion. J. Virol. 90(19), 8924–8933 (2016).

Welliver R, Monto AS, Carewicz O et al. Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial. JAMA 285(6), 748–754 (2001).

MJL C. Global coalition to accelerate COVID-19 clinical research in resource-limited settings. Lancet 395(10233), 1322–1325 (2020).

Harrison C. Coronavirus puts drug repurposing on the fast track. Nat. Biotechnol. 38(4), 379–381 (2020).

Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects. PLoS Med. 3(9), e343 (2006).

Chu CM, Cheng VC, Hung IF et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax 59(3), 252–256 (2004).

Su B, Wang Y, Zhou R et al. Efficacy and tolerability of lopinavir/ritonavir- and efavirenz-based initial antiretroviral therapy in HIV-1-infected patients in a tertiary care hospital in Beijing, China. Front. Pharmacol. 10, 1472 (2019).

Zhu S, Guo X, Geary K, Zhang D. Emerging therapeutic strategies for COVID-19 patients. Discoveries (Craiova) 8(1), e105 (2020).

Delang L, Abdelnabi R, Neyes J. Favipiravir as a potential countermeasure against neglected and emerging RNA viruses. Antiviral Res. 153, 85–94 (2018).

Devaux CA, Rolain JM, Colson P, Raoult D. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? Int. J. Antimicrob. Agents. 55(5), 105938 (2020).

FDA USFDA. Coronavirus (COVID-19) update: FDA issues emergency use authorization for potential COVID-19 treatment. (2020). http://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-issues-emergency-use-authorization-potential-covid-19-treatment

Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 178, 104787 (2020).

Findings on effective role of ivermectin against SARS-CoV-2.

Qu H, Ricklin D, Lambris JD. Recent developments in low molecular weight complement inhibitors. Mol. Immunol. 47(2–3), 185–195 (2009).

Wraith DC. The future of immunotherapy: a 20-year perspective. Front. Immunol. 8, 1668 (2017).

Gralinski LE, Sheahan TP, Morrison TE et al. Complement activation contributes to severe acute respiratory syndrome coronavirus pathogenesis. mBio 9(5), e01753–18 (2018).

Mastellos DC, Ricklin D, Lambris JD. Clinical promise of next-generation complement therapeutics. Nat. Rev. Drug Discov. 18(9), 707–729 (2019).

Gao T, Hu M, Zhang X et al. Highly pathogenic coronavirus N protein aggravates lung injury by MASP-2-mediated complement over-activation. MedRxiv. doi: https://doi.org/10.1101/2020.03.29.20041962 (2020) (Epub ahead of print).

Zhang W, Zhao Y, Zhang F et al. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): the perspectives of clinical immunologists from China. Clin. Immunol. 214, 108393 (2020).
60. Fagone P, Ciurleo R, Lombardo SD et al. Transcriptional landscape of SARS-CoV-2 infection dismantles pathogenic pathways activated by the virus, proposes unique sex-specific differences and predicts tailored therapeutic strategies. Autoimmun. Rev. 19(7), 102571 (2020).

61. Catanzaro M, Fagiani F, Racchi M, Corsini E, Govoni S, Lannì C. Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2. Signal Transduct. Target Ther. 5(1), 84 (2020).

62. Sabatini DM. Twenty-five years of mTOR: uncovering the link from nutrients to growth. Proc. Natl Acad. Sci. USA 114(45), 11818–11825 (2017).

63. Laplante M, Sabatini DM. mTOR signaling at a glance. J. Cell Sci. 122(Pt 20), 3589–3594 (2009).

64. Zheng Y, Li R, Liu S. Immunoregulation with mTOR inhibitors to prevent COVID-19 severity: a novel intervention strategy beyond vaccines and specific antiviral medicines. J. Med. Virol. doi:10.1002/jmv.26009 (2020) (Epub ahead of print).

65. Chi H. Regulation and function of mTOR signalling in T cell fate decisions. Nat. Rev. Immunol. 12(5), 325–338 (2012).

66. San Segundo D, Fernández-Fresnedo G, Gago M et al. Number of peripheral blood regulatory T cells and lymphocyte activation at 3 months after conversion to mTOR inhibitor therapy. Transplant. Proc. 42(8), 2871–2873 (2010).

67. Nicoletti F, Fagone P, Meroni P, McCubrey J, Bendtzen K. mTOR as a multifunctional therapeutic target in HIV infection. Drug Discov. Today 16(15–16), 715–721 (2011).

68. Nicoletti F, Lapenta C, Donati S et al. Inhibition of human immunodeficiency virus (HIV-1) infection in human peripheral blood leucocytes-SCID reconstituted mice by rapamycin. Clin. Exp. Immunol. 155(1), 28–34 (2009).

69. Donia M, McCubrey JA, Bendtzen K, Nicoletti F. Potential use of rapamycin in HIV infection. Br. J. Clin. Pharmacol. 70(6), 784–793 (2010).

70. Jia X, Liu B, Bao L et al. Delayed oseltamivir plus sirolimus treatment attenuates H1N1 virus-induced severe lung injury correlated with repressed NLPR3 inflammasome activation and inflammatory cell infiltration. PLoS Pathog. 14(11), e1007428 (2018).

71. Turner AP, Shaffer VO, Araki K et al. Sirolimus enhances the magnitude and quality of viral-specific CD8+ T-cell responses to vaccinia virus vaccination in rhesus macaques. Am. J. Transplant. 11(3), 613–618 (2011).

72. WHO. Vaccines. (2020). http://www.who.int/topics/vaccines/en/

73. Graham RL, Donaldson EF, Baric RS. A decade after SARS: strategies for controlling emerging coronaviruses. Nat. Rev. Microbiol. 11(12), 836–848 (2013).

74. Nascimento IP, Leite LC. Recombinant vaccines and the development of new vaccine strategies. Braz. J. Med. Biol. Res. 45(12), 1102–1111 (2012).

75. Bolles M, Deming D, Long K et al. A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge. J. Virol. 85(23), 12201–12215 (2011).

76. Tseng CT, Sbrana E, Iwata-Yoshikawa N et al. Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus. PLoS ONE 7(4), e35421 (2012).

77. Johnson J. What you need to know about the latest on the coronavirus – and a potential preventive vaccine. (2020). http://www.jnj.com/latest-news/what-you-need-to-know-about-coronavirus-and-a-potentialjohnson-johnson-vaccine

78. Sanofi. Sanofi joins forces with U.S. Department of Health and Human Services to advance a novel coronavirus vaccine. (2020). http://www.news.sanofi.us/index.php

79. Goodridge HS, Ahmed SS, Curtis N et al. Harnessing the beneficial heterologous effects of vaccination. Nat. Rev. Immunol. 16(6), 392–400 (2016).

80. Pollard AJ, Finn A, Curtis N. Non-specific effects of vaccines: plausible and potentially important, but implications uncertain. Arch. Dis. Child. 102(11), 1077–1081 (2017).

81. Arts RJW, Moorlag S, Novakovic B et al. A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge. J. Virol. 85(23), 12201–12215 (2011).

82. Arts RJW, Moorlag S, Novakovic B et al. A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge. J. Virol. 85(23), 12201–12215 (2011).

83. Arts RJW, Moorlag S, Novakovic B et al. A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge. J. Virol. 85(23), 12201–12215 (2011).

84. Arts RJW, Moorlag S, Novakovic B et al. A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge. J. Virol. 85(23), 12201–12215 (2011).

85. Arts RJW, Moorlag S, Novakovic B et al. A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge. J. Virol. 85(23), 12201–12215 (2011).

86. Arts RJW, Moorlag S, Novakovic B et al. A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge. J. Virol. 85(23), 12201–12215 (2011).

87. Arts RJW, Moorlag S, Novakovic B et al. A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge. J. Virol. 85(23), 12201–12215 (2011).

88. Arts RJW, Moorlag S, Novakovic B et al. A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge. J. Virol. 85(23), 12201–12215 (2011).

89. Arts RJW, Moorlag S, Novakovic B et al. A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge. J. Virol. 85(23), 12201–12215 (2011).

90. Arts RJW, Moorlag S, Novakovic B et al. A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge. J. Virol. 85(23), 12201–12215 (2011).

91. Arts RJW, Moorlag S, Novakovic B et al. A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge. J. Virol. 85(23), 12201–12215 (2011).

92. Arts RJW, Moorlag S, Novakovic B et al. A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge. J. Virol. 85(23), 12201–12215 (2011).

93. Arts RJW, Moorlag S, Novakovic B et al. A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge. J. Virol. 85(23), 12201–12215 (2011).

94. Arts RJW, Moorlag S, Novakovic B et al. A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge. J. Virol. 85(23), 12201–12215 (2011).

95. Arts RJW, Moorlag S, Novakovic B et al. A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge. J. Virol. 85(23), 12201–12215 (2011).

96. Arts RJW, Moorlag S, Novakovic B et al. A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge. J. Virol. 85(23), 12201–12215 (2011).

97. Arts RJW, Moorlag S, Novakovic B et al. A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge. J. Virol. 85(23), 12201–12215 (2011).

98. Arts RJW, Moorlag S, Novakovic B et al. A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge. J. Virol. 85(23), 12201–12215 (2011).

99. Arts RJW, Moorlag S, Novakovic B et al. A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge. J. Virol. 85(23), 12201–12215 (2011).

100. Arts RJW, Moorlag S, Novakovic B et al. A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge. J. Virol. 85(23), 12201–12215 (2011).
87. Koenig KL. Identify-isolate-inform: a modified tool for initial detection and management of Middle East Respiratory Syndrome patients in the emergency department. *West. J. Emerg. Med.* 16(5), 619–624 (2015).

88. Hussain W, Haleem KS, Khan I et al. Medicinal plants: a repository of antiviral metabolites. *Future Virol.* 12(6), 299–308 (2017).